Clinical Trials

A completed Phase IV clinical trial evaluated Norethisterone Enanthate to investigate the relationship between progestogen-only injectable contraception, recurrent bacterial vaginosis, and HIV risk among vulnerable female populations. Sponsored by a consortium of academic and clinical research institutions, the study aimed to generate key safety and efficacy data on the secondary physiological impacts of this contraceptive in real-world infectious disease settings.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02905890 Completed
Bacterial Vaginosis|HIV
London School of Hygiene and Tropical Medicine|Imperial College London|University of Liverpool|MRC/UVRI and LSHTM Uganda Research Unit
2017-10-02 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Norethisterone Enanthate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Norethisterone Enanthate functions as a synthetic progestin that selectively binds to and activates progesterone receptors, triggering negative feedback on the hypothalamic-pituitary-ovarian axis to suppress gonadotropin secretion and inhibit ovulation. This sustained hormonal activity alters cervical mucus composition and endometrial receptivity to prevent pregnancy, while also influencing vaginal microenvironment dynamics pertinent to bacterial vaginosis and HIV susceptibility.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.